Device Trial Radar · NCT07939360
Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction.
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Jun 12, 2026
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Essilor InternationalNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020. Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States. The expected duration of the study will be six (6) months, and subject participation will take approximately four (4) weeks, including three (4) visits; pretreatment visit, Treatment Day, two (2) week follow-up and four (4) week follow-up visits. The investigational therapy in this study is the use of low-level light therapy (LLLT) for the treatment of evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. Low-Level Light Therapy (LLLT) is a treatment that uses gentle light to help patient cells work better. The light is applied to the skin using special devices. This light can help repair cells that are damaged and improve the function of healthy cells. It may also warm the natural oils in patient eyelids and could reduce tiny mites that sometimes live near the eyelashes. These effects may support overall eye health and comfort. Participants will be randomized to receive treatment using the Equinox System (red mask) or iLux 2020 System ("iLux system"). There is a 50% chance participant will receive treatment with the Equinox System (red mask) and 50% chance participant will receive treatment with the iLux 2020 System. For treatment, participant will be placed in either the prone or supine position. Participant will then wear the red mask for 17 minutes. Special protective eyewear or eye protection is not indicated for this treatment; participant will be instructed to keep eyes closed to ensure full application of the treatment to the upper and lower lids and the periorbital area. Immediately after the treatment is finished, the mask will be removed and the meibomian glands will be manually expressed by a trained and qualified clinician.
Conditions
- Dry Eye
- Dry Eyes Chronic
Interventions
low-level light therapyDevice
Equinox mask used to deliver low-level light therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Equinox System not-inferiority to iLux® System with the respect of change from baseline to Week 4 in Meibomian Gland Score (MGS)Time frame: 4 weeks
- Equinox System not-inferiority to iLux® System with the respect of change from baseline to Week 4 in Tear Break-Up Time (TBUT)Time frame: 4 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
MRB Eye Consultants, LLC
Scottsdale, Arizona
East West Eye Institute
Torrance, California
Louisville Eye Center PLLC
Louisville, Kentucky
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.